Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 451 - 475 of 703 in total
EDI-200 is a fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1.
Investigational
HMI-204 is an adeno-associated virus serotype HSC15 expressing human arylsulfatase A
Investigational
RGX-202 is a recombinant AAV8 that contains a vector genome encoding a miniaturized dystrophin protein (microdystrophin).
Investigational
Investigational
ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis. The Company determined that the program was not meeting their...
Investigational
DTS-201 is a prodrug of doxorubicin, a widely used anti-cancer drug that Diatos intends to develop for the treatment of various solid tumors. It is activated in the tumor environment. DTS-201 may be suitable for the treatment of many types of solid tumors, including tumors sensitive to doxorubicin and potentially...
Investigational
Matched Description: … other tumors which are not currently treated with doxorubicin but which express high levels of CD-10* or
FAV-201 is a patient-specific immunotherapy for the treatment of T-cell lymphoma.
Investigational
Investigational
Investigational
OTL-201 is an investigational hematopoietic stem cell (HSC) gene therapy being developed by Orchard Therapeutics for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA). It consists of a lentiviral vector to insert a functional copy of the human N-Sulfoglucosamine Sulfohydrolase (SGSH) gene into autologous CD34+ hematopoietic stem cells.
Investigational
PYX-201 is an antibody-drug conjugate directed against the extra domain-B splice variant of fibronectin.
Investigational
SIG-205 is a Cultured human retinal pigment epithelial cells (ARPE-19) genetically modified with a non-viral vector to express human native alpha-L-iduronidase enzyme (hIDUA), encapsulated within two-layer modified alginate spheres
Investigational
OTL-203 is an autologous CD34+ enriched cell therapy that contains hematopoietic stem and progenitor cells transduced ex-vivo using a lentiviral vector encoding alpha-L-iduronidase gene.
Investigational
Velafermin was a novel investigational protein therapeutic, also known as fibroblast growth factor-20 (FGF-20), which promotes both epithelial and mesenchymal cell proliferation in vitro and has demonstrated activity in multiple animal models. Velafermin was investigated as a potential therapy for the prevention and treatment of oral mucositis by fostering the...
Investigational
Matched Synonyms: … RECOMBINANT HUMAN FIBROBLAST GROWTH FACTOR-20 ... FIBROBLAST GROWTH FACTOR 20 (HUMAN RECOMBINANT CG53135) …
Matched Description: … Velafermin was a novel investigational protein therapeutic, also known as fibroblast growth factor-20 ... (FGF-20), which promotes both epithelial and mesenchymal cell proliferation in vitro and has demonstrated …
E-2012 is a gamma secretase modulator that is being evaluated as a potential new treatment for Alzheimer's disease.
Investigational
VB-201 is under investigation in clinical trial NCT01001468 (Study to Assess VB-201 in Patients With Psoriasis).
Investigational
Investigational
Matched Name: … BVX-20
AB-201 is a CAR-NK cell therapy targeted against HER2. It is under investigation for the treatment of HER2-positive cancers, including breast and gastric carcinomas.
Investigational
CN-201 is a humanized anti-CD3/CD19 bispecific antibody.
Investigational
INGN 201(Advexin) is a replication-impaired adenoviral vector that carries the p53 gene, has been evaluated in both preclinical and clinical trials. Advexin is a well-tolerated and efficacious treatment for numerous cancers, both as monotherapy and in combination with radiation and/or chemotherapy agents.
Investigational
Matched Description: … efficacious treatment for numerous cancers, both as monotherapy and in combination with radiation and/or
PRO 2000 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials. It is being studied for the prevention of HIV infection and other sexually transmitted diseases. This medicine does not cure HIV infection or AIDS and is being studied to reduce...
Investigational
Matched Description: … This medicine does not cure HIV infection or AIDS and is being studied to reduce the risk of passing …
Matched Categories: … Compounds used in a research, industrial, or household setting …
CAM2029 is a new ready-to-use, long-acting octreotide formulation being developed for the long-term treatment of acromegaly, carcinoid syndrome and vasoactive intestinal peptide (VIP)-producing tumours. CAM2029 was found to provide long-acting release of octreotide resulting in a statistically significant suppression of a clinical biomarker insulin-like growth factor 1 (IGF-1) over the...
Investigational
Withdrawn
OTX-2002 is a bicistronic messenger ribonucleic acid (mRNA) encoding for ZF-DNMT and ZF-KRAB proteins, encapsulated in a lipid nanoparticle (LNP).
Investigational
ISB 2001 is a T cell-engaging antibody that targets BCMA, CD38, and CD3.
Investigational
Displaying drugs 451 - 475 of 703 in total